15 reports

Global Addiction Disorder Epidemiology and Patient Flow Analysis - 2017 ##.

  • Addiction Disorder
  • Mental Health
  • United States
  • World
  • Forecast

Europe Addiction Disorder Epidemiology and Patient Flow Analysis - 2017 ##.

  • Addiction Disorder
  • Europe
  • France
  • Germany
  • Forecast
  • Official Title
  • Target

ALCOHOL ADDICTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2020* ALCOHOL ADDICTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2020* ALCOHOL ADDICTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2020* Source: GlobalD

  • Addiction Disorder
  • Clinical Trial
  • Pharmaceutical
  • United States
  • World

Global Addiction Disorders Epidemiology and Patient Flow Analysis - 2016 ##.

  • Addiction Disorder
  • Mental Health
  • United States
  • World
  • Forecast
  • Clinical Trial profile. 320 Trial Title
  • Target

Risperidone for Bipolar Disorder with Comorbid Substance Use Disorder Divalproex ER vs.

  • Addiction Disorder
  • Clinical Trial
  • Opioid
  • World
  • Alkermes plc
  • Target

Risperidone for Bipolar Disorder with Comorbid Substance Use Disorder Divalproex ER vs.

  • Addiction Disorder
  • Clinical Trial
  • Pharmaceutical
  • United States
  • World

With preclinical data showing efficacy in multiple types of addiction and compulsive disorders, the initial target planned for OMS## is nicotine addiction.

  • Addiction Disorder
  • Antiseptics
  • Pharmaceutical
  • United States
  • Product Initiative

Specialty treatment services provide treatment relating to eating disorders and addiction.

  • Addiction Disorder
  • Specialty Hospital
  • World
  • Acadia Healthcare Company, Inc.
  • Universal Health Services, Inc.
  • DEMAND DETERMINANTS CONTINUED
  • MAJOR MARKETS CONTINUED

The more common types include anxiety disorders, mood disorders, psychotic disorders, eating disorders, impulse control and addiction disorders and personality disorders.

  • Addiction Disorder
  • Mental Health
  • Pathology
  • United States
  • Forecast
  • INTERVEXION THERAPEUTICS LLC
  • DRUG ADDICTION - PIPELINE BY INTERVEXION THERAPEUTICS LLC, H1 2020

PROTAGENIC THERAPEUTICS IS DEVELOPING PT-## (TCAP-##) FOR THE TREATMENT OF DEPRESSION, ANXIETY, MOOD DISORDERS, OPIOID ADDICTION AND OTHER NEURODEGENERATIVE DISORDERS INCLUDING STRESS-RELATED DISORDERS.

  • Addiction Disorder
  • Therapy
  • United States
  • Company
  • Product Initiative
  • DEC 12, 2017: EMBERA NEUROTHERAPEUTICS TO PRESENT AT THE 10TH ANNUAL BIOTECH SHOWCASE
  • OCT 18, 2017: ALTASCIENCES CONDUCTS ALCOHOL DRUG-DRUG INTERACTION STUDY FOR AMYGDALA NEUROSCIENCES

PROTAGENIC THERAPEUTICS IS DEVELOPING PT-## (TCAP-##) FOR THE TREATMENT OF DEPRESSION, ANXIETY, MOOD DISORDERS, OPIOID ADDICTION AND OTHER NEURODEGENERATIVE DISORDERS INCLUDING STRESS-RELATED DISORDERS.

  • Addiction Disorder
  • United States
  • Company
  • Product Initiative
  • MediciNova, Inc.
  • PRODUCTS & SERVICES CONTINUED

Mental illness and substance abuse disorder According to the National Alliance on Mental Illness (NAMI), ##. ## million adults have co-occurring mental health and addiction disorders.

  • Addiction Disorder
  • Health Care Provider
  • Mental Health
  • United States
  • Forecast

With preclinical data showing efficacy in multiple types of addiction and compulsive disorders, the initial target planned for OMS## is nicotine addiction.

  • Addiction Disorder
  • Antiseptics
  • Pharmaceutical
  • United States
  • Product Initiative
  • Target
  • Clinical Trial profile. 318 Trial Title

Risperidone for Bipolar Disorder with Comorbid Substance Use Disorder Divalproex ER vs.

  • Addiction Disorder
  • Clinical Trial
  • Pharmaceutical
  • United States
  • World
  • NICOTINE ADDICTION - PIPELINE BY CV SCIENCES INC

The company develops medications to treat addiction and related disorders.

  • Addiction Disorder
  • Opioid
  • Company
  • Product Initiative
  • Omeros Corporation